Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer: a retrospective review.
Affiliation
Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester, UK. stephenmangar@supaworld.comIssue Date
2006-02
Metadata
Show full item recordAbstract
BACKGROUND AND PURPOSE: To identify objective pre-treatment clinical parameters that could be used to predict for patients at high risk of requiring enteral tube feeding prior to head and neck radiotherapy. PATIENTS AND METHODS: A retrospective study was conducted on 160 consecutive patients attending for radiotherapy assessment. Regression analysis was used to determine various pre-treatment nutritional and tumour specific parameters associated with the use of enteral nutrition either before (prophylactic) or during (reactive) radiotherapy (RT). The significant parameters identified were then selected into categorical variables and compared between those who needed reactive enteral nutrition and the remainder of the group who did not. These results were used to generate predictive factors that could be used to identify those at high risk of malnutrition during RT for whom early or prophylactic enteral nutrition should be considered. RESULTS: Fifty patients required enteral feeding of which 60% required this prior to radiotherapy. Multivariate analysis identified the following factors to be significant--body mass index, performance status (PS), advanced stage, pre-treatment weight loss, low serum albumin and protein, age, and smoking. The most significant categorical predictive parameters for reactive enteral feeding were stage 3-4 disease, PS 2-3, and smoking >20/day. The combination of these factors predicted a 75% chance of needing enteral nutrition. CONCLUSION: Nutritional assessment is important prior to radiotherapy and is multifactorial. Using a combination of relatively simple and objective parameters, (performance status, smoking and disease stage) it is possible to identify those at high risk of needing enteral nutrition prior to starting RT.Citation
Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer: a retrospective review. 2006, 78 (2):152-8 Radiother OncolJournal
Radiotherapy and OncologyDOI
10.1016/j.radonc.2005.12.014PubMed ID
16466819Type
ArticleLanguage
enISSN
0167-8140ae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2005.12.014
Scopus Count
Collections
Related articles
- [Evaluation of a predictive score for malnutrition in patients treated by irradiation for head and neck cancer: a retrospective study in 127 patients].
- Authors: Lescut N, Personeni E, Desmarets M, Puyraveau M, Hamlaoui R, Servagi-Vernat S, Bosset JF, Nguyen F
- Issue date: 2013 Nov
- Predictors of weight loss during radiation therapy.
- Authors: Beaver ME, Matheny KE, Roberts DB, Myers JN
- Issue date: 2001 Dec
- Prophylactic gastrostomy placement and early tube feeding may limit loss of weight during chemoradiotherapy for advanced head and neck cancer, a preliminary study.
- Authors: Wiggenraad RG, Flierman L, Goossens A, Brand R, Verschuur HP, Croll GA, Moser LE, Vriesendorp R
- Issue date: 2007 Oct
- Nutritional support during radiotherapy for head and neck cancer: the role of prophylactic feeding tube placement.
- Authors: Cady J
- Issue date: 2007 Dec
- Serum trace elements in tube-fed neurological dysphagia patients correlate with nutritional indices but do not correlate with trace element intakes: case of patients receiving enough trace elements intake.
- Authors: Obara H, Tomite Y, Doi M
- Issue date: 2008 Aug
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)